Alloferon is a novel immunomodulatory peptide consisting of 13 amino acids and has a molecular weight of 1,265 daltons. Alloferon was originally isolated from the blood of an experimentally infected insect, the blow fly Calliphora vicina, but EntoPharm succeeded in synthesize it. Most of the preclinical trials and all of the clinical trials were conducted with synthetic version of Alloferon. Alloferon shows no sequence similarity to any known human or animal cytokine, but does show structural similarities to the hemagglutinin sector of the influenza virus, responsible for adhesion on the membrane of the host cell. In addition to its current injectable form as used in clinical trials, Alloferon is being developed for intranasal administration. EntoPharm is also examining the possibilities of developing diverse formulation of Alloferon for oral or transdermal administration with its strategic partner, Pacific Pharm. Alloferon is now being synthesized at the peptide lab of Alloferon Co. in Russia. It is currently produced in lyophilized powder form and packaged in ampoules but will be available in vials for the Korean market. Alloferon is usually dissolved in 1.0 milligram of saline by clinicians for injection purposes.